Reviva Pharmaceuticals (NASDAQ:RVPH) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) released its earnings results on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.29, FiscalAI reports.

Reviva Pharmaceuticals Trading Down 55.7%

RVPH stock traded down $0.44 during midday trading on Wednesday, reaching $0.35. 13,049,007 shares of the company’s stock traded hands, compared to its average volume of 367,588. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $23.20. The business has a 50-day moving average price of $1.45 and a two-hundred day moving average price of $6.08.

Analysts Set New Price Targets

RVPH has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Maxim Group cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Finally, D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RVPH. XTX Topco Ltd raised its stake in shares of Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares during the period. State Street Corp raised its stake in shares of Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the period. Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals by 87.6% during the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after purchasing an additional 489,711 shares during the period. Millennium Management LLC raised its stake in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares during the period. Finally, Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.